View ValuationRapid Dose Therapeutics 将来の成長Future 基準チェック /06現在、 Rapid Dose Therapeuticsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 30Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025.お知らせ • May 28Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in fundingRapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.お知らせ • May 27Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery TechnologyRapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.お知らせ • Feb 19Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.お知らせ • Dec 11Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share.お知らせ • Oct 31Rapid Dose Therapeutics Corp. announced that it has received CAD 0.851 million in fundingOn October 30, 2024. the company has closed the final tranche of the transactionお知らせ • Jun 27Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024.お知らせ • Mar 26Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing.お知らせ • Jan 20Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in fundingRapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent.お知らせ • Sep 23Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of DirectorsRapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023.お知らせ • Jun 03Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023.お知らせ • May 11Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian MarketRapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Rapid Dose Therapeutics は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:RDTC.F - アナリストの将来予測と過去の財務データ ( )CAD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数11/30/20253-4-1-1N/A8/31/20253-5-1-1N/A5/31/20252-5-1-1N/A2/28/20252-5-1-1N/A11/30/20242-6-2-2N/A8/31/20241-5-3-3N/A5/31/20241-5-3-3N/A2/29/20241-4-2-2N/A11/30/20231-4-1-1N/A8/31/20231-3-1-1N/A5/31/20231-3-1-1N/A2/28/20231-4-1-1N/A11/30/20221-9-1-1N/A8/31/20221-10-1-1N/A5/31/20221-9-2-2N/A2/28/20222-8-3-3N/A11/30/20212-2-4-4N/A8/31/20212-2-4-4N/A5/31/20212-1-3-3N/A2/28/20211-2-2-2N/A11/30/20200-200N/A8/31/2020-1-5-1-1N/A5/31/20200-5-2-1N/A2/29/20200-8-4-3N/A11/30/20190-17-6-4N/A8/31/20191-15N/A-4N/A5/31/20190-14N/A-3N/A2/28/2019N/A-11N/A-2N/A11/30/20180-3N/A-1N/A8/31/2018N/A-2N/A-1N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: RDTC.Fの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: RDTC.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: RDTC.Fの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: RDTC.Fの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: RDTC.Fの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: RDTC.Fの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 23:29終値2026/05/15 00:00収益2025/11/30年間収益2025/02/28データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Rapid Dose Therapeutics Corp. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Peter-Thilo HaslerSphene Capital GmbH
お知らせ • Jun 30Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 27, 2025.
お知らせ • May 28Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 3 million in fundingRapid Dose Therapeutics Corp. announced a equity private placement financing to issue 13,636,364 units at a price of CAD 0.22 per Unit for gross proceeds of CAD 3,000,000.08 on May 27, 2025. Each Unit will consist of one common share and one common share purchase warrant. Each Warrant will be exercisable to acquire one Common Share at a price of CAD 0.34 per Common Share for a term of two (2) years from the date of issuance of such Warrant. The Financing may close in one or more tranches. All securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.
お知らせ • May 27Rapid Dose Therapeutics and Aavishkar Oral Strips File Two Key Patents for Innovative Nicotine Delivery TechnologyRapid Dose Therapeutics Corp. announced the filing of two critical patent applications in partnership with Aavishkar Oral Strips Pvt. Ltd. These patents cover both dissolvable and non-dissolvable oral nicotine strips - representing a breakthrough in nicotine delivery. These next-generation strips are designed for administration, similar to existing oral pouches, but with significantly faster absorption, improved bioavailability, and no need for removal after use. While provisional patents were submitted in July 2024, the new international PCT applications filed with the World Intellectual Property Organization (WIPO) mark a major advancement. The filings extended potential protection to up to 158 jurisdictions worldwide, reinforcing the strategic global positioning of this novel nicotine replacement therapy. Unlike traditional pouches that rely on slower buccal absorption, RDT's dissolvable QuickStrip nicotine strip enables nicotine delivery in under 2 minutes-offering rapid onset of effect. In parallel, the non-dissolvable variant provides extended release in a slim, discreet, and user-friendly format, appealing to a broad spectrum of adult users and aligning with evolving regulatory preferences. A Global Opportunity to Support smoking and Vaping Cessation. According to the World Health Organization, more than 1.3 billion people worldwide use tobacco products or vape nicotine, contributing to over 7 million deaths annually directly attributable to tobacco use. Independent research indicates that up to 60% of smokers want to quit, yet the lack of effective, convenient and discreet alternatives remain a critical barrier to success. QuickStrip aims to change that. Building on Momentum: Partnership with Global Tobacco Leader. These patent filings follow the previously announced pre-commercialization development agreements with a leading global tobacco company, as previously disclosed by RDT on January 28, 2025. The collaboration encompasses early-stage development and validation of QuickStrip nicotine technologies - underscoring industry recognition and growing confidence in RDT's ability to deliver innovative, consumer-centric nicotine alternatives. RDT and its partner Aavishkar remain committed to operating within stringent regulatory frameworks and, together with their partner(s), will pursue the necessary approvals to bring these products to market across multiple jurisdictions. Regulatory submissions and clinical validation activities are scheduled for the coming calendar quarters.
お知らせ • Feb 19Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 5 million in fundingRapid Dose Therapeutics Corp. announced an equity private placement financing to issue 20,833,333 common shares at an issue price of CAD 0.24 per share for gross proceeds of CAD 4,999,999.92 on February 18, 2025. The Financing may close in one or more tranches. The securities issued on the Financing will be subject to a four-month hold from the applicable date of closing.
お知らせ • Dec 11Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced that an equity private placement financing of 24,000,000 units at a price of CAD 0.25 per unit for gross proceeds of CAD 6,000,000 on December 10, 2024. Each Unit will consist of one Common Share and one Common Share Purchase Warrant. Each Warrant will be exercisable for one Common Share for a period of 2 years from the date of issue, at a price of CAD 0.33 per Common Share.
お知らせ • Oct 31Rapid Dose Therapeutics Corp. announced that it has received CAD 0.851 million in fundingOn October 30, 2024. the company has closed the final tranche of the transaction
お知らせ • Jun 27Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 21, 2024.
お知らせ • Mar 26Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 6 million in fundingRapid Dose Therapeutics Corp. announced a private placement of up to 35,294,117 common shares at a price of CAD 0.17 per common share for gross proceeds of up to CAD 5,999,999.89 on March 25, 2024. The private placement may close in one or more tranches. The securities issued will be subject to a four month hold from the applicable date of closing.
お知らせ • Jan 20Rapid Dose Therapeutics Corp. announced that it expects to receive CAD 7 million in fundingRapid Dose Therapeutics Corp. announced a private placement of 41,176,470 units at a price of CAD 0.17 per unit for the gross proceeds of CAD 7,000,000 on January 19, 2024. Each unit consists of one common share and one share purchase warrant. Each warrant will be exercisable to acquire one common share at a price of CAD 0.20 per common share for a term of two years from the date of issuance of such warrant. The financing may close in one or more tranches. All securities issued on the financing will be subject to a four month hold from the applicable date of closing. As a part of the transaction, the company may pay a cash commission equal to 6% of the aggregate gross proceeds as placement agent fee. The company shall also issue such number of non-transferable agent warrants as is equal to 6% of the number of Units issued to investors in the financing that were introduced to the company by the agent.
お知らせ • Sep 23Rapid Dose Therapeutics Corp. Announces the Resignation of Andrew Duckman from the Company's Board of DirectorsRapid Dose Therapeutics Corp. announced the resignation of Andrew Duckman from the Company's board of directors effective September 18, 2023.
お知らせ • Jun 03Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023Rapid Dose Therapeutics Corp., Annual General Meeting, Aug 01, 2023.
お知らせ • May 11Rapid Dose Therapeutics Corp. Launches QuickStrip™ Dental Products in the Canadian MarketRapid Dose Therapeutics Corp. has launched two unique dental QuickStrip™ products across the country. The QuickStrip technology will initially have two applications in the dental industry: LQS™, a Lidocaine thin film to be used professionally as a topical anesthetic application to provide pain free dental treatment and assisting in allowing pain free local anesthetic where injection is required. XyliStrip™, oral dissolving thin film strip, to be used for the treatment of dry mouth and xerostomia.